Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guihong Wan

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Journal of the National Cancer Institute|February 21, 2022
Pre-Existing Autoimmune Disease and Mortality in Patients Treated with Anti-PD-1 and Anti-PD-L1 TherapyKimberly Tang, Bruce C Tiu, Guihong Wan, et al.
Journal of the American Academy of Dermatology|January 30, 2024
Timing of cutaneous immune-related adverse events impacts survival in patients with cancer treated with immune-checkpoint inhibitors: A multi-institutional cohort studyHannah Rashdan, Shijia Zhang, Guihong Wan, et al.
Journal of the American Academy of Dermatology|September 20, 2023
Checkpoint inhibitor antibody type influences the development of cutaneous immune-related adverse events: A multi-institutional studyKatie Roster, Ahmad Rajeh, Nga Nguyen, et al.
Journal of the American Academy of Dermatology|February 11, 2023
Patterns in utilization of health care services and medications among patients with cutaneous immune-related adverse events: A population-level cohort studyBonnie W Leung, Michael Ryan Collier, Bruce C Tiu, et al.
Medrxiv : the Preprint Server for Health Sciences|June 10, 2025
Machine learning prediction for early-stage melanoma outcomes: recurrence-free survival, disease-specific survival, and overall survivalGuihong Wan, Hannah Rashdan, Olivia M Burke, et al.
The British Journal of Dermatology|April 27, 2024
De novo autoimmune connective tissue disease and mortality in patients treated with anti-programmed death receptor-1 and anti-programmed death-ligand 1 therapy: a population-level cohort studyKimberly Tang, Ahmad Rajeh, Katharina S Shaw, et al.
Medrxiv : the Preprint Server for Health Sciences|January 20, 2025
Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse eventsSara Khattab, Guihong Wan, Suzanne Xu, et al.
The British Journal of Dermatology|February 1, 2026
The Impact of Clinicopathologic Features on the Prognosis of Thin Melanomas: A Retrospective Cohort AnalysisEmma Beagles, Sara Khattab, Olivia M Burke, et al.
Journal for Immunotherapy of Cancer|May 12, 2025
Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse eventsSara Khattab, Guihong Wan, Suzanne Xu, et al.
Briefings in Bioinformatics|May 3, 2024
SpatialCells: automated profiling of tumor microenvironments with spatially resolved multiplexed single-cell dataGuihong Wan, Zoltan Maliga, Boshen Yan, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Journal of the National Cancer Institute|February 21, 2022
Pre-Existing Autoimmune Disease and Mortality in Patients Treated with Anti-PD-1 and Anti-PD-L1 TherapyKimberly Tang, Bruce C Tiu, Guihong Wan, et al.
Journal of the American Academy of Dermatology|January 30, 2024
Timing of cutaneous immune-related adverse events impacts survival in patients with cancer treated with immune-checkpoint inhibitors: A multi-institutional cohort studyHannah Rashdan, Shijia Zhang, Guihong Wan, et al.
Journal of the American Academy of Dermatology|September 20, 2023
Checkpoint inhibitor antibody type influences the development of cutaneous immune-related adverse events: A multi-institutional studyKatie Roster, Ahmad Rajeh, Nga Nguyen, et al.
Journal of the American Academy of Dermatology|February 11, 2023
Patterns in utilization of health care services and medications among patients with cutaneous immune-related adverse events: A population-level cohort studyBonnie W Leung, Michael Ryan Collier, Bruce C Tiu, et al.
Medrxiv : the Preprint Server for Health Sciences|June 10, 2025
Machine learning prediction for early-stage melanoma outcomes: recurrence-free survival, disease-specific survival, and overall survivalGuihong Wan, Hannah Rashdan, Olivia M Burke, et al.
The British Journal of Dermatology|April 27, 2024
De novo autoimmune connective tissue disease and mortality in patients treated with anti-programmed death receptor-1 and anti-programmed death-ligand 1 therapy: a population-level cohort studyKimberly Tang, Ahmad Rajeh, Katharina S Shaw, et al.
Medrxiv : the Preprint Server for Health Sciences|January 20, 2025
Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse eventsSara Khattab, Guihong Wan, Suzanne Xu, et al.
The British Journal of Dermatology|February 1, 2026
The Impact of Clinicopathologic Features on the Prognosis of Thin Melanomas: A Retrospective Cohort AnalysisEmma Beagles, Sara Khattab, Olivia M Burke, et al.
Journal for Immunotherapy of Cancer|May 12, 2025
Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse eventsSara Khattab, Guihong Wan, Suzanne Xu, et al.
Briefings in Bioinformatics|May 3, 2024
SpatialCells: automated profiling of tumor microenvironments with spatially resolved multiplexed single-cell dataGuihong Wan, Zoltan Maliga, Boshen Yan, et al.
Pageof 4